SCHEMBL4386263

SCHEMBL4386263

c1cnc2c(Oc3cccc4cccnc34)cccc2c1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.72
LMNA P02545 5/20 0.58
MAPT P10636 4/20 0.58
HTT P42858 3/20 0.58
SMN1; SMN2 Q16637 3/20 0.58
MMP2 P08253 2/20 0.58
TSHR P16473 2/20 0.58
GMNN O75496 1/20 0.58
TP53 P04637 1/20 0.58
HSP90AA1 P07900 1/20 0.58
CYP3A4 P08684 1/20 0.58
CYP2D6 P10635 1/20 0.58
MMP9 P14780 1/20 0.58
ALOX15 P16050 1/20 0.58
NFKB1 P19838 1/20 0.58
MMP8 P22894 1/20 0.58
CCR1 P32246 1/20 0.58
THPO P40225 1/20 0.58
MTOR P42345 1/20 0.58
MMP13 P45452 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9446986 0.87 KDM4E (0.63) KDM4ELMNAMAPTHTTSMN1; SMN2
SCHEMBL546185 0.86 RAB9A (0.68) KDM4ELMNAMAPTHTTSMN1; SMN2
Hydrochloric Acid SCHEMBL9052059 0.85 RAB9A (0.66) KDM4ELMNAMAPTHTTSMN1; SMN2
Hydrochloric Acid SCHEMBL27496748 0.84 KDM4E (0.59) KDM4ELMNAMAPTHTTSMN1; SMN2
Tetraethylene Glycol SCHEMBL6031544 0.83 KDM4E (0.57) KDM4ELMNAMAPTHTTSMN1; SMN2
SCHEMBL6516869 0.83 KDM4E (0.58) KDM4ELMNAMAPTHTTSMN1; SMN2
SCHEMBL17924042 0.83 MAPT (0.59) KDM4ELMNAMAPTHTTSMN1; SMN2
SCHEMBL21753772 0.83 KDM4E (0.58) KDM4ELMNAMAPTHTTSMN1; SMN2
SCHEMBL6750955 0.83 KDM4E (0.58) KDM4ELMNAMAPTHTTSMN1; SMN2
SCHEMBL22772422 0.83 KDM4E (0.58) KDM4ELMNAMAPTHTTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090227626-A1 NOVEL POLYQUINOLINE DERIVATIVES AND THERAPEUTIC USE THEREOF PALUMED S.A. (FR) 2009-09-10 US claimed
US-20240201165-A1 NANOPORE-BASED ANALYSIS OF ANALYTES RIJKSUNIVERSITEIT GRONINGEN (NL) 2024-06-20 US disclosed
WO-2024117910-A1 NANOBODY-FUNCTIONALIZED BIOLOGICAL NANOPORES AND MEANS AND METHODS RELATED THERETO RIJKSUNIVERSITEIT GRONINGEN (NL) 2024-06-06 WO disclosed
WO-2024091124-A1 NANOPORE-BASED ANALYSIS OF PROTEINS RIJKSUNIVERSITEIT GRONINGEN (NL) 2024-05-02 WO disclosed
EP-1919894-B1 NOVEL POLYQUINOLINE DERIVATIVES AND THE THERAPEUTIC USE THEREOF PALUMED SA (FR) 2014-10-08 EP disclosed
US-8324196-B2 Polyquinoline derivatives and the therapeutic use thereof PALUMED S.A. (FR) 2012-12-04 US disclosed
US-20120277265-A1 NOVEL POLYQUINOLINE DERIVATIVES AND THE THERAPEUTIC USE THEREOF CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.) (FR) 2012-11-01 US disclosed
US-8247396-B2 Polyquinoline derivatives and therapeutic use thereof PALUMED S.A. (FR) 2012-08-21 US disclosed
US-20090227626-A1 NOVEL POLYQUINOLINE DERIVATIVES AND THERAPEUTIC USE THEREOF PALUMED S.A. (FR) 2009-09-10 US disclosed
CN-100514706-C Gravure plate, method for forming light-emitting layer or hole-injection layer using the same, and organic light-emitting device DAINIPPON PRINTING CO LTD (JP) 2009-07-15 CN disclosed
US-20060051699-A1 Radiation-sensitive elements and their storage stability KODAK POLYCHROME GRAPHICS LLC (US) 2006-03-09 US disclosed
CN-1703437-A bismuth-catalyzed polyurethane compositions SIKA TECHNOLOGY AG (CH) 2005-11-30 CN disclosed
US-6479669-B2 PEPTIDE MIMETICS PHARM-ECO LABORATORIES, INC. 2002-11-12 US disclosed
CN-1353103-A Functional dendritic molecular material and its preparing process UNIV FUDAN (CN) 2002-06-12 CN disclosed
US-20020010342-A1 AMINO ACID DERIVATIVES AND METHODS OF MAKING THE SAME JOHNSON MATTHEY PHARMACEUTICAL MATERIALS, INC. 2002-01-24 US disclosed
EP-0725563-A1 MARINE STRUCTURE J.C. HEMPEL'S SKIBSFARVE-FABRIK A/S (DK) 1996-08-14 EP disclosed
WO-1995011592-A1 MARINE STRUCTURE J.C. HEMPEL'S SKIBSFARVE-FABRIK A/S (DK) 1995-05-04 WO disclosed
EP-0387499-B1 Substituted oxine ethers and their use as pesticides BAYER AG (DE) 1993-12-22 EP disclosed
EP-0387499-A3 SUBSTITUTED OXINE ETHERS AND THEIR USE AS PESTICIDES 1990-11-22 EP disclosed
EP-0387499-A2 Substituted oxine ethers and their use as pesticides BAYER AG (DE) 1990-09-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120277265-A1 NOVEL POLYQUINOLINE DERIVATIVES AND THE THERAPEUTIC USE THEREOF HTT, APP, PSEN1 KDM4E 4293/4885LMNA 1091/4885MAPT 14/4885
US-20020010342-A1 AMINO ACID DERIVATIVES AND METHODS OF MAKING THE SAME DAO, PRMT8, PRMT5 KDM4E 865/4885LMNA 2105/4885MAPT 4376/4885
US-20090227626-A1 NOVEL POLYQUINOLINE DERIVATIVES AND THERAPEUTIC USE THEREOF HTT, UBQLN2, UBQLN1 KDM4E 3878/4885LMNA 625/4885MAPT 235/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.